Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumoursGeert Spierenburg, Hans Gelderblom, Michiel A. J. van de Sande et al.|European Journal of Cancer|2022Cited by 33
Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approachesGeert Spierenburg, Hans Gelderblom, L. van der Heijden et al.|Expert Opinion on Therapeutic Targets|2022Cited by 30
Management of tenosynovial giant cell tumour of the foot and ankleGeert Spierenburg, C. L. M. H. Gibbons, Sarah Lancaster et al.|The Bone & Joint Journal|2021Cited by 22
Surgical management of 144 diffuse‐type TGCT patients in a single institution: A 20‐year cohort studyGeert Spierenburg, Michiel A. J. van de Sande, L. van der Heijden et al.|Journal of Surgical Oncology|2022Cited by 15
Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort studyGeert Spierenburg, L. van der Heijden, Eric L. Staals et al.|European Journal of Surgical Oncology|2024Cited by 9